News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aclaris Therapeutics Initiates IND-Directed Program for A-101 for the Treatment of Seborrheic Keratosis, Common Type of Skin Tumor



11/6/2013 10:15:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MALVERN, Pa.--(BUSINESS WIRE)--Aclaris Therapeutics Inc., a privately-held specialty pharmaceutical company dedicated to developing dermatological therapeutics, announced today the initiation of the first clinical trial of the company’s lead product A-101, a topically-applied therapy. A-101 is being investigated in adult patients for the removal of seborrheic keratosis, one of the most common types of benign skin tumors.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES